ASND vs PRQR
Ascendis Pharma A/S and ProQR Therapeutics N.v., side by side — 5 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | PRQR |
|---|---|---|
| Revenue | €720.1M | €15.9M |
| Net income | €-228.0M | €-42.2M |
| Gross margin | 86.8% | · |
| Net margin | −31.7% | −265.2% |
| Return on equity | · | −61.2% |
| Diluted EPS | −€3.76 | −€0.40 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | €-53.8M |
| Equity | · | €49.4M |
| Net debt / equity | · | −1.77× |
| Current ratio | 1.04× | 3.09× |
| Revenue CAGR 5y | 153.0% | · |
| Profit CAGR 5y | · | · |
ASND bills 45.3× the revenue of PRQR, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
5 years side by side
| Fiscal year | ASND | PRQR |
|---|---|---|
| FY2025 | €720.1M | €15.9M |
| FY2024 | €363.6M | €18.9M |
| FY2023 | €266.7M | €6.5M |
| FY2022 | €51.2M | €3.6M |
| FY2021 | €7.8M | €1.3M |
Bottom line
| Fiscal year | ASND | PRQR |
|---|---|---|
| FY2025 | €-228.0M | €-42.2M |
| FY2024 | €-378.1M | €-27.8M |
| FY2023 | €-481.4M | €-28.1M |
| FY2022 | €-583.2M | €-64.4M |
| FY2021 | €-383.6M | €-60.7M |
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +€704,226,000 | ASND |
| FY2024 | +€344,736,000 | ASND |
| FY2023 | +€260,204,000 | ASND |
| FY2022 | +€47,580,000 | ASND |
| FY2021 | +€6,443,000 | ASND |
ASND has reported the higher revenue in every one of these 5 fiscal years. The gap has widened since the earliest year compared.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PRQR's net margin has been more volatile than ASND's over the 3 comparable fiscal years — 114.3 percentage points of standard deviation against 60.8.
3 of 6 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ASND led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 6 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's return on equity has been more volatile than PRQR's over the 8 comparable fiscal years — 20.4 percentage points of standard deviation against 18.8.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ASND and PRQR over these 8 fiscal years — ASND led in 6 and PRQR in 2.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.